QuickSwitch™ Tetramer Platform and SARS-CoV-2 Peptides
Functional screening of peptides for MHC class I binding is essential for vaccine development and immune system monitoring. A fast, high-throughput and user-friendly assay system with potential for clinical immune monitoring is needed today more than ever. With QuitchSwitch™ from MBL, a 90-minute test system is available that allows the experimental evaluation of the MHC binding ability of candidate peptides. This is particularly important for the screening of immunogenic peptides of infectious agents or cancer neoantigens.
Advantages of the QuickSwitch™ Tetramer platform:
- Validation of in silico pre-selected peptides for their MHC-binding properties
- Generation of new specific tetramers for immune monitoring
- Functional stability studies for MHC-binding peptides
- Epitope comparison for epitope mapping of better binding peptides
MBL QuickSwitch™: Peptide exchange, quantification, cell staining and flow cytometric analysis within one day!
The proteome of the new coronavirus SARS-CoV-2 is known, potential B- and T-cell epitopes have been identified and published, e.g. by Grifoni et al. Peptide screening with the QuickSwitch™ platform allows to identify and validate the binding of predicted peptide sequences of COVID-19 virus proteins in the most common alleles: HLA-A2, A11, A24, A3 and HLA-DR1, DR4, DR15. For this purpose, MBL has built up a portfolio of relevant COVID-19 peptides, which is constantly being expanded.
>> QuickSwitch™ Quant Kits in the BIOZOL web shop
